After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

Lilly hopes that "patients see themselves reflected in the commercial," says Ashley Diaz-Granados, SVP of U.S. immunology ...

Like most drugs, Ebglyss may cause mild to serious side effects ... you’re encouraged to call Eli Lilly and Company (the drugmaker) at 800-LillyRx (800-545-5979) to share your experience ...

Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has achieved complete skin clearance after three years in 50% of patients with moderate-to-severe atopic dermatitis (AD) in a Phase III trial. The US ...

New data shows Ebglyss achieved deep and sustained response ... Also Read: Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding Additionally, 87% achieved or ...

Drugs for metabolic diseases ... is tipped for sales of $1.6 billion. 4) Eli Lilly and Almirall's Ebglyss (lebrikizumab), an anti-IL-13 antibody for atopic dermatitis that offers less frequent ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

However, Lilly saw strength in other drugs as well, with overall non-incretin ... and ezcema medication Ebglyss. Further out, the company is looking for a full-scale launch of Orforglipron in ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...